Check out what we’ve been up to and where we can connect!
September 21, 2021
The results from this study provide important information about the clinical management of hospitalized patients with COVID-19. Additional research is needed to identify a method that can be used to accurately prioritize patients with COVID-19 at risk of critical illness or death.
June 23, 2021
Tiziana and FHI Clinical announce collaboration on a Phase 2 study in Brazil to evaluate the safety, tolerability and efficacy of intranasal Foralumab in hospitalized patients with severe COVID-19 and pulmonary inflammation.
April 24, 2021
Results of the Adaptive COVID-19 Treatment Trial (ACTT)-2 investigating combination treatment with baricitinib, a Janus kinase inhibitor, and remdesivir for the treatment of COVID-19 in hospitalized adults were published in the New England Journal of Medicine (NEJM) on March 4, 2021, showing that the combination treatment was superior to remdesivir alone.
March 29, 2021
Phase I/II studies to evaluate human placental hematopoietic stem cell–derived natural killer (NK) cell therapy to treat COVID-19 in hospitalized adults are currently ongoing as part of our partnership with the Infectious Disease Research Institute (IDRI).
April 18-21, 2022
Attending the World Vaccine Congress 2022? Stop by our booth for a presentation about COVID-19 vaccine development, conducting trials in sub-Saharan Africa or using novel methods to ensure equitable access to clinical research. Members of our team will also be available to talk about our capabilities and services.
April 19, 2022
Join this roundtable, hosted by FHI Clinical, to discuss and compare experiences with COVID-19 and how those might be relevant when designing trials for other indications.
April 12, 2022
Join us for an episode of Careers in Pharma, a webinar featuring Daniel Joffe, Senior Clinical Project Manager at FHI Clinical, as he talks about his role as a project manager, challenges he faces and skills he uses.
March 17-19, 2022
At the 5th annual WAC-CREP conference, FHI Clinical employees are presenting findings from research being conducted within the Partnership for Research on Vaccines and Infectious Diseases in Liberia (PREVAIL) network.
February 22, 2022
Join us for this plenary discussion in which experts in infectious diseases discuss how real-world epidemiology data, site capacity data and biosurveillance methodology could help identify TB-prevalent populations during protocol design, helping to ensure an adequate sample for TB vaccine development.
February 22-25, 2022
Attending the Global Forum on TB Vaccines? Visit our booth to learn more about our services or schedule a meeting with our team.
FHI Clinical Headquarters
359 Blackwell Street, Suite 200
Durham, NC 27701 USA